July 2005 - June 2007
University of Massachusetts Medical School Fellowship in Nephrology Worcester, MA

July 2004 - June 2005
University of Massachusetts Medical School Chief Resident, Internal Medicine Residency Program Worcester, MA

July 2001 - June 2004
University of Massachusetts Medical School Categorical, Internal Medicine Residency Program Worcester, MA

August 1997 - June 2001
St. George's University School of Medicine Medical Doctorate Degree Grenada, WI / Bay Shore, NY

Sept 1991 - June 1995
University of California, Los Angeles Bachelor of Science Psychology Los Angeles, CA

July 2007
American Board of Internal Medicine, Board Eligible in Nephrology

August 2005 - Devember 2015
American Board of Internal Medicine Certification

March 2005 - 2007
Massachusetts Medical Licensure

2006
California Licensure

2006 - Present
National Kidney Foundation

2006 - Present
American Society of Nephrology

2006 - Present
Renal Physicians Associations

2003 - 2004
Massachusetts Medical Society, Resident Physicians Fellowship appointed Communications Committee Representative

2001 - Present
Massachusetts Medical Society

2001 - Present
American College of Physicians, American Society of Internal Medicine

2006 - 2007
University of Massachusetts Medical School 3rd Year Medical Student Renal Lecture Series: Acute Renal Failure

2006 - 2007
University of Massachusetts Graduate School of Nursing, Worcester, MA Renal Lecure Series: Acute Renal Failure

August 2006
University of Massachusetts Medical School, Dept. of Medicine, Resident Noon Conference: Neflhrolithiasis

2005 - Present
University of Massachusetts Medical School, Worcester, MA Clinical Instructor

2005 - 2006
University of Massachusetts Medical School, Worcester, MA Chief Resident Conducted Morning Reports and Noon Conferences Involved in Administrative Duties Within the Department of Medicine

2005 - 2006
University of Massachusettes Medical School, Worecester, MA Physical Diagnosis Instructor for Second Year Medical Students

2006 - 2007
Pleiotropic Effects of Starins in Patients with Hypertension and Microalbuminuria.
Under John Danziger, M.D., Division of Renal Medicine.
Massachusetts Medical Center, Worcester, MA (Under IRB Review)
2000 - 2001

Study of Cox-2 Expression
Division of Renal Medicine
Brookdale University Hospital, Brooklyn, NY
Performed Immunohistochemical Studies and Nephrectomies

1992 - 1995
Lab Assistant / Researcher
Division of Pediatric Hematology / Oncology
University of California, Los Angeles Medical Center
Studied Various Aspect of Ofn-Myc Expression in Neuroblastoma

1) Wada, RK; Pai, DS; Huang, J; Yamashiro, JM; Sidell, N: "Interferon-Gamma and Retinoic Acid Down Regulate N-myc in Neuroblastoma Through Complimentary Mechanism of Action" Cancer Letter 1997 Dec 23; 121(2):181-8

2) Goodman, LA; Lui, BC; Thiele, CJ; Schmidy, ML; Cohn, SL; Yamashiro, JM; Pai, DS; Ikegaki, N; Wada, RKl "Modulation of N-myc Expression Alters the Invasiveness of Neuroblastoma" Clinical Experimental Metastasis. 1997 Mar; 15(2) 130-9

3) Woodruff, KA; "Cell Type Specific Activity of the N-myc Promoter in the Human Neuroblastoma Cells is Mediated by a Down Stream Silencer" Oncofene 1995 Apr 6; 10(7): 1335-41

1) Iota Epsilon Alpha Honor Society Member, St. Gorge's University School of Medicine, 1997 - 2001
2) Dean's List, St. George's University School of Medicine, 1997 - 2001
3) Geoffery Boune Scholarship Recipient, St. George's University, School of Medicine

A Phase III, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Center Trial Evaluating the Efficacy and Safety of XXX in Adult Patiets on Chronic Haemodialysis.

A Phase III, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epogen.

A Phase IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX.

A Phase II, Randomized Double-Blind, Placebo-Controlled, Multi-Center, to Evaluate the Safety and Efficacy of XXX in Patients with Nephropaty Due to Type 2 Diabetes.

Patient Focus Group for Qualatative Assessment of Anemia Associated with Chronic Kidney Disease.

A Multicenter, Randomized, Double-Blink Study to Evaluate the Efficacy and Safety of XXX in Patients with Type 2 Diabetes Mellitus and End Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control.

A Phase II Study of the Safety and Efficacy of XXX Injection for the Maintenace Treatment of Anemia in Subjects with Chronic Renal Failure on Hemodialysis, of Do Not Requre Dialysis and Previously Treated with Darbepoetin Alfa.

The National Institutes of Heath (NIH) Office of Extramural Research Certifies that David Pai Successfully Completed the NIH Web-Based Training Course "Protecting Human Research Participants" 07-01-2009. Certification Number 250174.